CA2803004A1 - Oral formulations of kinase inhibitors - Google Patents

Oral formulations of kinase inhibitors Download PDF

Info

Publication number
CA2803004A1
CA2803004A1 CA2803004A CA2803004A CA2803004A1 CA 2803004 A1 CA2803004 A1 CA 2803004A1 CA 2803004 A CA2803004 A CA 2803004A CA 2803004 A CA2803004 A CA 2803004A CA 2803004 A1 CA2803004 A1 CA 2803004A1
Authority
CA
Canada
Prior art keywords
formulation
kinase inhibitor
polyethylene glycol
oil
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2803004A
Other languages
English (en)
French (fr)
Inventor
Andrew Xian Chen
Yali J. Tsai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poniard Pharmaceuticals Inc
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Publication of CA2803004A1 publication Critical patent/CA2803004A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2803004A 2010-06-29 2011-06-28 Oral formulations of kinase inhibitors Abandoned CA2803004A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35969410P 2010-06-29 2010-06-29
US61/359,694 2010-06-29
PCT/US2011/042162 WO2012006081A1 (en) 2010-06-29 2011-06-28 Oral formulation of kinase inhibitors

Publications (1)

Publication Number Publication Date
CA2803004A1 true CA2803004A1 (en) 2012-01-12

Family

ID=45441513

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2803004A Abandoned CA2803004A1 (en) 2010-06-29 2011-06-28 Oral formulations of kinase inhibitors

Country Status (10)

Country Link
US (1) US9375402B2 (OSRAM)
EP (1) EP2588081A4 (OSRAM)
JP (1) JP5936609B2 (OSRAM)
CN (1) CN103313697B (OSRAM)
AU (1) AU2011276552B2 (OSRAM)
CA (1) CA2803004A1 (OSRAM)
MX (1) MX340819B (OSRAM)
NZ (1) NZ604583A (OSRAM)
WO (1) WO2012006081A1 (OSRAM)
ZA (1) ZA201300009B (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9174946B2 (en) 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
CA2827171C (en) 2011-02-17 2019-04-09 Cancer Therapeutics Crc Pty Limited Fak inhibitors
RU2664700C2 (ru) 2012-05-10 2018-08-21 Пейнреформ Лтд. Депо-составы местного анестетика и способы их получения

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656182A (en) 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US20040006005A1 (en) * 2002-07-02 2004-01-08 Sanjay Bhanot Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU1167702A (en) * 2000-10-11 2002-04-22 Cephalon Inc Compositions comprising modafinil compounds
TW200409629A (en) 2002-06-27 2004-06-16 Bristol Myers Squibb Co 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
US20080119515A1 (en) * 2003-03-10 2008-05-22 M Arshad Siddiqui Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
CN101119976B (zh) 2005-02-18 2010-12-22 泰博特克药品有限公司 抑制hiv的2-(4-氰基苯氨基)嘧啶氧化物衍生物
EP1959926A1 (en) * 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
JP5592647B2 (ja) 2006-04-28 2014-09-17 メルク・シャープ・アンド・ドーム・コーポレーション 制御された析出による６，６−ジメチル−３−アザ−ビシクロ［３．１．０］ヘキサン−アミド化合物の析出および単離のための方法、ならびにこれを含む医薬処方物
PT2046292E (pt) * 2006-07-21 2010-04-26 Novartis Ag Formulações de éteres benzimidazolil-piridílicos
CN103588704B (zh) * 2007-03-16 2016-09-14 斯克里普斯研究学院 粘着斑激酶抑制剂
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2009105498A1 (en) 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
US8569298B2 (en) 2008-06-17 2013-10-29 Astrazeneca Ab Pyridine compounds
CN102648197A (zh) 2009-08-12 2012-08-22 铂雅制药公司 促进细胞凋亡和抑制转移的方法
WO2011133668A2 (en) 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
ZA201300009B (en) 2013-09-25
MX2012014982A (es) 2013-07-03
MX340819B (es) 2016-07-26
EP2588081A4 (en) 2014-12-10
US9375402B2 (en) 2016-06-28
JP2013529686A (ja) 2013-07-22
JP5936609B2 (ja) 2016-06-22
AU2011276552B2 (en) 2015-09-03
WO2012006081A1 (en) 2012-01-12
NZ604583A (en) 2015-04-24
CN103313697B (zh) 2016-06-01
US20140206692A1 (en) 2014-07-24
EP2588081A1 (en) 2013-05-08
CN103313697A (zh) 2013-09-18
AU2011276552A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
US11020375B2 (en) Edaravone dosage form
JP6513576B2 (ja) 抗がん剤および使用
ES2784843T3 (es) Complejos de Sirolimus y sus derivados, procedimiento para la preparación de los mismos y composiciones farmacéuticas que los contienen
KR101716878B1 (ko) 글리세롤 지방산에스테르유도체 또는 프로필렌글리콜 지방산에스테르유도체를 함유한 두타스테리드와 타다라필의 복합 캡슐제제 조성물 및 이의 제조방법
KR101064901B1 (ko) 난수용성 항암제와 신규 블록 공중합체를 포함하는 미셀조제물
CA2240595A1 (en) Taxane composition and method
US20210346302A1 (en) Pharmaceutical Formulation
US20150272943A1 (en) Solid dispersion with improved solubility comprising tetrazole derivative as an active ingredient
US6316497B1 (en) Self-emulsifying systems containing anticancer medicament
US9375402B2 (en) Oral formulations of kinase inhibitors
RS52131B (sr) Nove kompozicije na bazi taksoida
CN104710433A (zh) 苯丁酸氮芥衍生物、制备方法及应用
CN115850248A (zh) 一种替尼类抗肿瘤药物化合物及其制备方法和应用
IL173110A (en) Semi-solid formulations for the oral administration of taxoids
JP6014252B2 (ja) ネパデュタントを含有する小児用経口液体組成物
AU2007262493A1 (en) Pharmaceutical composition for oral administration
KR101612259B1 (ko) 고농도의 탁산을 포함하는 경구 투여용 약학 조성물
RU2742650C2 (ru) Фармацевтический состав
CA3240171A1 (en) A formulation for an effective oral administration of ciclopirox with no adversal gasterointestinal toxicity
KR20240160567A (ko) 리포솜 조성물 및 리포솜 함유 약학적 조성물
US20200146973A1 (en) Pharmaceutical Composition for Oral Delivery of Hydrophobic Small Molecule Drug and Hydrophilic Small Molecule Drug Concurrently
WO2024210196A1 (ja) スルホンアミド誘導体を含有する自己乳化組成物および自己乳化製剤
CN117247389A (zh) 一种靶向药物化合物及其制备方法和应用
KR20220124891A (ko) 나파모스타트 또는 이의 염을 포함하는 에멀젼을 포함하는 약제학적 제제 및 이의 제조 방법
AU2015261692A1 (en) Oral formulation of kinase inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160617

FZDE Dead

Effective date: 20181227